Carl Whatling
Impact in
- Cancer Research top 10%
- Protease and Inhibitor Mechanisms
- Pharmacology top 5%
- Microbial Natural Products and Biosynthesis
- Inflammatory mediators and NSAID effects
Papers in
-
- Antiplatelet Therapy and Cardiovascular Diseases 6
- Co-authors
- Timothy D. WarnerSven NylanderPer ErikssonAnders HamstenWilliam L. McPheatAdriano HenneyDirk WalterAndreas M. Zeiher
- Journals
- Arteriosclerosis Thrombosis and Vascular Biology (4 papers)Circulation (3 papers)Journal of Medicinal Chemistry (3 papers)Clinical and Translational Science (2 papers)British Journal of Clinical Pharmacology (2 papers)
- Partner nations
- SwedenUnited KingdomUnited States
In The Last Decade
Carl Whatling
44 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 113
- Cancer Research 247
- Pharmacology 234
- Internal Medicine 50
- Cardiology and Cardiovascular Medicine 276
- Nephrology 85
Countries citing papers authored by Carl Whatling
This map shows the geographic impact of Carl Whatling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Whatling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Whatling more than expected).
Fields of papers citing papers by Carl Whatling
This network shows the impact of papers produced by Carl Whatling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Whatling. The network helps show where Carl Whatling may publish in the future.
Co-authors
The 25 scholars most cited alongside Carl Whatling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2023 | 2 | |
| 3 | 2023 | 22 | |
| 4 | 2022 | 1 | |
| 5 | 2022 | 6 | |
| 6 | 2021 | 3 | |
| 7 | 2021 | 4 | |
| 8 | 2021 | 8 | |
| 9 | 2019 | 31 | |
| 10 | Abstract 11146: AZD3366-an Optimized Recombinant Human Apyrase Combining Anti Platelet, Anti Inflammatory and Tissue Protective Actions With Low Bleeding Risk for Potential Mitigation of Thromboembolic Complications | 2019 | 1 |
| 11 | 2019 | 83 | |
| 12 | 2017 | 35 | |
| 13 | 2017 | 40 | |
| 14 | 2015 | 34 | |
| 15 | 2011 | 175 | |
| 16 | 2008 | 2 | |
| 17 | 2004 | 32 | |
| 18 | 2000 | 24 | |
| 19 | 1993 | 6 | |
| 20 | 1990 | 13 |
About Carl Whatling
Carl Whatling is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine, Cancer Research, Physiology and Nephrology, having authored 44 papers that have together received 1.5k indexed citations. Recurring topics across this work include Protease and Inhibitor Mechanisms (7 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers), Inflammatory mediators and NSAID effects (6 papers), Lipoproteins and Cardiovascular Health (5 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (3 papers), Pharmacogenetics and Drug Metabolism (3 papers), Atherosclerosis and Cardiovascular Diseases (3 papers) and Estrogen and related hormone effects (3 papers). The work is most often cited by research in Cancer Research (247 citations), Pharmacology (234 citations), Internal Medicine (50 citations), Cardiology and Cardiovascular Medicine (276 citations) and Nephrology (85 citations). Carl Whatling has collaborated with scholars based in Sweden, United Kingdom and United States. Frequent co-authors include Timothy D. Warner, Sven Nylander, Per Eriksson, Anders Hamsten, William L. McPheat, Adriano Henney, Dirk Walter, Andreas M. Zeiher, Mark J. Buttner and Keith Chater. Their work appears in journals such as Arteriosclerosis Thrombosis and Vascular Biology, Circulation, Journal of Medicinal Chemistry, Clinical and Translational Science and British Journal of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.